BETA BIONICS INC (NASDAQ:BBNX) reported second-quarter results after the market close on Wednesday, posting revenue that came in essentially in line with analyst expectations while delivering a narrower-than-anticipated net loss per share. Investors responded by pushing the stock up approximately 3% in after-hours trading, a sign that the market focused on the earnings beat and on the company’s solid margin progress rather than on the modest revenue shortfall.
Revenue and Earnings Summary
For the quarter ended June 30, 2026, Beta Bionics generated net sales of $32.0 million, just 0.2% below the consensus estimate of $32.07 million. While the revenue figure was effectively inline with expectations, the company’s bottom-line performance surprised to the upside; non-GAAP earnings per share of -$0.53 came in $0.08 better than the -$0.61 the Street had penciled in. Key operational highlights from the quarter include:
- Net sales rose 38% year over year, driven by a 153% surge in the Pharmacy Benefit Plan channel to $11.6 million.
- Gross margin expanded 524 basis points to 59.0%, exceeding the company’s prior guidance range.
- New patient starts increased sequentially by 10% to 20%, with 69% of new starts switching from multiple daily injections.
- Cash, cash equivalents, and investments totaled $225.2 million, providing a strong runway into 2027.
Loss from operations narrowed to $25.6 million (negative 80% of sales) from $19.9 million (negative 86% of sales) a year ago. Adjusted EBITDA was negative $17.7 million, or negative 55% of sales, compared with negative $14.5 million or negative 63% of sales in the prior-year period.
Guidance and Analyst Expectations
Management reaffirmed its full-year 2026 revenue guidance of $131 million to $136 million, while analysts collectively expect $136.4 million — a figure at the upper end of that range. The company also increased its gross margin forecast to 58.5% to 59.5%, up from the previous 57.5% to 59.5% band, reflecting confidence in continued cost leverage. For the current quarter, analysts are projecting sales of approximately $35.8 million, implying a growth trajectory that aligns with management’s annual target.
Market Reaction
The after-market advance of more than 3% suggests that the combination of an EPS beat, an improved gross margin outlook, and a strong uptake in the PBP channel outweighed the minor revenue inline reading. The stock had declined about 10% over the prior month, so the positive reaction may also reflect relief that the second-quarter report contained no negative surprises. Longer-term, the initiation of a pivotal trial for the iLet in type 2 diabetes and plans to commercialize the Mint patch pump by mid-2027 add to the pipeline narrative.
Investors looking for deeper historical earnings data can review the company’s past quarterly reports on this earnings details page. For future-period revenue and EPS estimates, the latest consensus projections are available through the forecast overview.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Beta Bionics (NASDAQ:BBNX) Q2: EPS Beat and Margin Progress Lift Shares 3% After Hours
BETA BIONICS INC (NASDAQ:BBNX) reported second-quarter results after the market close on Wednesday, posting revenue that came in essentially in line with analyst expectations while delivering a narrower-than-anticipated net loss per share. Investors responded by pushing the stock up approximately 3% in after-hours trading, a sign that the market focused on the earnings beat and on the company’s solid margin progress rather than on the modest revenue shortfall.
Revenue and Earnings Summary
For the quarter ended June 30, 2026, Beta Bionics generated net sales of $32.0 million, just 0.2% below the consensus estimate of $32.07 million. While the revenue figure was effectively inline with expectations, the company’s bottom-line performance surprised to the upside; non-GAAP earnings per share of -$0.53 came in $0.08 better than the -$0.61 the Street had penciled in. Key operational highlights from the quarter include:
Loss from operations narrowed to $25.6 million (negative 80% of sales) from $19.9 million (negative 86% of sales) a year ago. Adjusted EBITDA was negative $17.7 million, or negative 55% of sales, compared with negative $14.5 million or negative 63% of sales in the prior-year period.
Guidance and Analyst Expectations
Management reaffirmed its full-year 2026 revenue guidance of $131 million to $136 million, while analysts collectively expect $136.4 million — a figure at the upper end of that range. The company also increased its gross margin forecast to 58.5% to 59.5%, up from the previous 57.5% to 59.5% band, reflecting confidence in continued cost leverage. For the current quarter, analysts are projecting sales of approximately $35.8 million, implying a growth trajectory that aligns with management’s annual target.
Market Reaction
The after-market advance of more than 3% suggests that the combination of an EPS beat, an improved gross margin outlook, and a strong uptake in the PBP channel outweighed the minor revenue inline reading. The stock had declined about 10% over the prior month, so the positive reaction may also reflect relief that the second-quarter report contained no negative surprises. Longer-term, the initiation of a pivotal trial for the iLet in type 2 diabetes and plans to commercialize the Mint patch pump by mid-2027 add to the pipeline narrative.
Investors looking for deeper historical earnings data can review the company’s past quarterly reports on this earnings details page. For future-period revenue and EPS estimates, the latest consensus projections are available through the forecast overview.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »